HOUSTON, March 20, 2018 /PRNewswire/ -- In a step toward democratizing the financing of a breakthrough cancer drug technology, CNS Pharmaceuticals, Inc., announced today the launch of its equity crowdfunding campaign on Republic, utilizing new equity crowdfunding securities laws called regulation CF or Reg CF for short, to support the development of Berubicin, its lead drug candidate for the treatment of Glioblastoma, the most aggressive type of brain cancer.
Republic link: https://republic.co/cns-pharmaceuticals
Berubicin was discovered at the prestigious University of Texas MD Anderson...
The comment you're trying to see no longer exists.
Republic does not verify information provided by companies on this Portal and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Portal can be found by searching the EDGAR database.